28125165|t|Inhibitor Selectivity for Cyclin-Dependent Kinase 7: A Structural, Thermodynamic, and Modelling Study
28125165|a|Deregulation of the cell cycle by mechanisms that lead to elevated activities of cyclin-dependent kinases (CDK) is a feature of many human diseases, cancer in particular. We identified small-molecule inhibitors that selectively inhibit CDK7, the kinase that phosphorylates cell-cycle CDKs to promote their activities. To investigate the selectivity of these inhibitors we used a combination of structural, biophysical, and modelling approaches. We determined the crystal structures of the CDK7 -selective compounds ICEC0942 and ICEC0943 bound to CDK2, and used these to build models of inhibitor binding to CDK7. Molecular dynamics (MD) simulations of inhibitors bound to CDK2 and CDK7 generated possible models of inhibitor binding. To experimentally validate these models, we gathered isothermal titration calorimetry (ITC) binding data for recombinant wild-type and binding site mutants of CDK7 and CDK2. We identified specific residues of CDK7, notably Asp155, that are involved in determining inhibitor selectivity. Our MD simulations also show that the flexibility of the G-rich and activation loops of CDK7 is likely an important determinant of inhibitor specificity similar to CDK2.
28125165	0	9	Inhibitor	T103	UMLS:C0014432
28125165	26	51	Cyclin-Dependent Kinase 7	T103	UMLS:C0255652
28125165	55	65	Structural	T082	UMLS:C0678594
28125165	86	95	Modelling	T062	UMLS:C0600115
28125165	96	101	Study	T062	UMLS:C2603343
28125165	102	132	Deregulation of the cell cycle	T038	UMLS:C1516331
28125165	183	207	cyclin-dependent kinases	T103	UMLS:C0243045
28125165	209	212	CDK	T103	UMLS:C0243045
28125165	235	240	human	T204	UMLS:C0086418
28125165	241	249	diseases	T038	UMLS:C0012634
28125165	251	257	cancer	T038	UMLS:C0006826
28125165	287	301	small-molecule	T103	UMLS:C1328819
28125165	302	312	inhibitors	T103	UMLS:C0014432
28125165	338	342	CDK7	T103	UMLS:C0255652
28125165	348	354	kinase	T103	UMLS:C0031727
28125165	360	374	phosphorylates	T038	UMLS:C0031715
28125165	375	385	cell-cycle	T038	UMLS:C0007586
28125165	386	390	CDKs	T103	UMLS:C0243045
28125165	460	470	inhibitors	T103	UMLS:C0014432
28125165	496	506	structural	T082	UMLS:C0678594
28125165	508	519	biophysical	T091	UMLS:C0005553
28125165	525	534	modelling	T062	UMLS:C0600115
28125165	565	583	crystal structures	T103	UMLS:C0444626
28125165	591	595	CDK7	T103	UMLS:C0255652
28125165	607	616	compounds	T103	UMLS:C1254351
28125165	617	625	ICEC0942	T103	UMLS:C1254351
28125165	630	638	ICEC0943	T103	UMLS:C1254351
28125165	648	652	CDK2	T103	UMLS:C0108855
28125165	678	684	models	T170	UMLS:C0026344
28125165	688	697	inhibitor	T103	UMLS:C0014432
28125165	709	713	CDK7	T103	UMLS:C0255652
28125165	754	764	inhibitors	T103	UMLS:C0014432
28125165	774	778	CDK2	T103	UMLS:C0108855
28125165	783	787	CDK7	T103	UMLS:C0255652
28125165	807	813	models	T170	UMLS:C0026344
28125165	817	826	inhibitor	T103	UMLS:C0014432
28125165	839	853	experimentally	T062	UMLS:C0681814
28125165	869	875	models	T170	UMLS:C0026344
28125165	945	956	recombinant	T103	UMLS:C0034861
28125165	957	966	wild-type	T017	UMLS:C1883559
28125165	971	983	binding site	T103	UMLS:C0005456
28125165	984	991	mutants	T103	UMLS:C1564139
28125165	995	999	CDK7	T103	UMLS:C0255652
28125165	1004	1008	CDK2	T103	UMLS:C0108855
28125165	1045	1049	CDK7	T103	UMLS:C0255652
28125165	1059	1065	Asp155	T103	UMLS:C0004015
28125165	1100	1109	inhibitor	T103	UMLS:C0014432
28125165	1211	1215	CDK7	T103	UMLS:C0255652
28125165	1254	1263	inhibitor	T103	UMLS:C0014432
28125165	1287	1291	CDK2	T103	UMLS:C0108855